COMPUTATIONAL DRUG REPROPOSING TO IDENTIFY SARS-COV-2 MPRO INHIBITORS: MOLECULAR DOCKING, ADMET ANALYSIS, AND IN-SILICO/IN-VITRO TOXICITY STUDY

  • Mohammed Farrag El-Behairy Department of Organic and Medicinal Chemistry, Faculty of Pharmacy, University of Sadat City, Sadat City, Egypt.
  • Marwa AA Fayed Department of Pharmacognosy, Faculty of Pharmacy, University of Sadat City, Sadat City, Egypt.
  • Rasha M. Ahmed Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Misr International University, Cairo, Egypt.
  • Inas A. Abdallah Department of Analytical Chemistry, Faculty of Pharmacy, University of Sadat City, Sadat City, Egypt.
10.22270/ujpr.v7i5.837

Keywords:

ADMET, Computational chemistry, fragment-based drug discovery, Simeprevir, COVID-19, Structure–activity relationships

Abstract

Aim and Objective: After the COVID-19 outbreak, drug repurposing has emerged as an effective and fast approach for combating the SARS-CoV-2 crisis. in this work, computational drug repurposing has been utilized to identify new SARS-CoV-2Mpro inhibitors.

Methods: Comparative molecular docking studies were used to evaluate the activity of the commercially available oral antiviral drug simeprevir and its degradation products (compounds 1–5) against the main protease (Mpro)of SARS-CoV-2 (PDB ID: 6lu7; resolution: 2.16 Å). Moreover, the ADMET and in-silico toxicity properties of the acidic (compounds 1–3) and oxidative (compounds 4 and 5) degradation products of simeprevir were predicted.

Results: Docking studies revealed good binding affinities for compounds (1–5) against Mpro of SARS-CoV-2, with binding free energies ranging from −6.23 to −7.65 kcal/mol. The acidic degradant 2 exhibited the best affinity and was superior to simeprevir and a natural ligand. All compounds were expected to be safe to the CNS.

Conclusion: Compounds 1, 4, and 5 were expected to possess good human intestinal absorption, whereas compounds 2 and 3 appeared to have moderate intestinal absorption.

                        

Peer Review History:

Received: 5 August 2022; Revised: 9 September; Accepted: 20 October; Available online: 15 November 2022

Academic Editor: Dr. DANIYAN Oluwatoyin Michaelorcid22.jpg, Obafemi Awolowo University, ILE-IFE, Nigeria, toyinpharm@gmail.com

Received file: 6.gif                            Reviewer's Comments:download_logo_r_29189.gif

Average Peer review marks at initial stage: 5.5/10

Average Peer review marks at publication stage: 7.0/10

Reviewers:

orcid22.jpgDr. Gehan Fawzy Abdel Raoof Kandeel, Pharmacognosy Department, National Research Centre, Dokki, 12622,  Giza, Egypt, gehankandeel9@yahoo.com 

orcid22.jpgDr. Nicola Micale, University of Messina, Italy,  nmicale@unime.it

orcid22.jpgProf. Cyprian Ogbonna ONYEJI, Obafemi Awolowo University, Ile-Ife, Nigeria, conyeji@oauife.edu.ng

Downloads

Download data is not yet available.
Crossmark
Statistics
195 Views | 120 Downloads
Dimension Citations

Published

2022-11-15

How to Cite

El-Behairy, M. F., M. A. Fayed, R. M. Ahmed, and I. A. Abdallah. “COMPUTATIONAL DRUG REPROPOSING TO IDENTIFY SARS-COV-2 MPRO INHIBITORS: MOLECULAR DOCKING, ADMET ANALYSIS, AND IN-SILICO/IN-VITRO TOXICITY STUDY”. Universal Journal of Pharmaceutical Research, vol. 7, no. 5, Nov. 2022, doi:10.22270/ujpr.v7i5.837.

Issue

Section

Research Articles
Share |